Immunologic Memory 5 Years after Meningococcal A/C Conjugate Vaccination in Infancy

Citations Over TimeTop 10% of 2001 papers

Abstract

Infant vaccination with meningococcal conjugates may provide long-term protection against disease. Antibody levels and immunologic memory were assessed in 5-year-old Gambian children who received meningococcal A/C conjugate vaccination (MenA/C) in infancy. At 2 years, they were randomized to receive a booster of MenA/C (conjugate group), meningococcal A/C polysaccharide (MPS group), or inactivated polio vaccine (IPV group). All groups were revaccinated with 10 microg MPS at 5 years of age, as were 39 previously unvaccinated age-matched control subjects. Before revaccination, titers were higher in the conjugate and MPS groups than in control subjects (P or =5 years; however, MPS challenge at 2 years interfered with a subsequent memory response.

Related Papers

• → Enter B and W: two new meningococcal vaccine programmes launched(2015)107 cited
• → Neisseria meningitidisB vaccines(2011)46 cited
• → National and regional differences in meningococcal vaccine recommendations for individuals at an increased risk of meningococcal disease(2023)7 cited
• → Genome-based study of a spatio-temporal cluster of invasive meningococcal disease due to Neisseria meningitidis serogroup C, clonal complex 11(2016)22 cited
• → Meningococcal Vaccines(2007)9 cited